Cytoplasmic dsRNA induces the expression of OCT3/4 and NANOG mRNAs in differentiated human cells

Guanming Wang1, Takahisa Kouwaki1, Kazuki Mugikura2, Masaaki Okamoto1,2, Hiromi Takaki2, Kenji Funami2, Tsukasa Seya2,3*, Hiroyuki Oshiumi1*

1Department of Immunology, Graduate School of Medical Sciences, Faculty of Life Sciences, Kumamoto University, 1-1-1 Honjo, Chuo-ku, Kumamoto 860-8556 Japan; 2Nebuta Research Institute for Life Sciences, Aomori University, Kohbata 2-3-1, Aomori, 030-0943, Japan; 3Department of Vaccine Immunology, Graduate School of Medicine, Hokkaido University, Kita 15, Nishi 7, Kita-ku, Sapporo, 060-8638, Japan.

Running title: RLRs-mediated OCT3/4 expression

*To whom corresponding should be addressed: Hiroyuki Oshiumi, Department of Immunology, Faculty of Life Sciences, Kumamoto University, 1-1-1 Honjo, Chuo-ku, Kumamoto, Japan 860-8556; oshiumi@kumamoto-u.ac.jp; Tel. +81-96-373-5136.: Tsukasa Seya, Nebuta Research Institute for Life Sciences, Aomori University, Kohbata 2-3-1, Aomori, 030-0943, Japan 860-8556; seya-tu@pop.med.hokudai.ac.jp,

Keywords: innate immunity, RNA helicase RIG-I, mitochondrial antiviral signaling protein (MAVS), octamer-binding protein 3/4 (OCT3/4), POU class 5 homeobox 1 (POU5F1), antiviral response, pattern recognition receptor (PRR), cell signaling

ABSTRACT
Cytoplasmic dsRNA is recognized by RNA helicase RIG-I (RIG-I) and melanoma differentiation-associated protein 5 (MDA5), triggering induction of the innate immune response via the mitochondrial antiviral signaling protein (MAVS). In contrast, extracellular dsRNA is internalized into endosomes and recognized by Toll-like receptor 3 (TLR3), which triggers signaling via the Toll-like receptor adaptor molecule 1 (TICAM-1). Poly I:C is a synthetic dsRNA analog and increases the expression of octamer-binding protein 3/4 (OCT3/4), NANOG, and SRY-box (SOX) mRNAs during pluripotency induction. However, the mechanism underlying this increase is unclear. Here, we focused on the mechanism of poly I:C-induced expression of stem cell–specific genes in human somatic cells. Addition of poly I:C to human fibroblast culture medium did not increase OCT3/4 mRNA, cytoplasmic dsDNAs, such as salmon-sperm DNA and poly dA:dT, did not. Interestingly, the expression of NANOG, SOX2, Krüppel-like factor 4 (KLF4), and proto-oncogene c-Myc was also increased by cytoplasmic dsRNA. Of note, siRNAs that silenced MAVS and interferon regulatory factor 1 (IRF1) expression reduced OCT3/4 levels after stimulation with poly I:C; however, an NF-κB inhibitor and siRNA-mediated knockdown of proto-oncogene c-Jun did not significantly reduce the mRNA levels. We conclude that cytoplasmic dsRNA increases the expression of stem cell–specific genes in human somatic cells in a MAVS- and IRF1-dependent manner.

The innate immune system is essential for protection against viruses and bacteria at early phases of infections (1). Pattern recognition receptors (PRRs), such as Toll-like receptors (TLRs) and RIG-I-like receptors (RLRs), recognize pathogen-associated molecular patterns (PAMPs) and trigger the signals to produce type I
interferon (IFN) and pro-inflammatory cytokines (2). In case of viral infection, viral double-stranded RNA (dsRNA) in the endosomes is recognized by TLR3, whereas cytoplasmic dsRNA is recognized by RIG-I and MDA5 (3). TLR3 utilizes the TICAM-1 adaptor to trigger the downstream signaling, and RIG-I and MDA5 activate the signaling via the MAVS adaptor (4). In addition to dsRNA, exogenous dsDNA can be recognized by PRRs. TLR9 senses non-methylated CpG DNA and induces pro-inflammatory cytokine expression via the MyD88 adaptor (5). In contrast, cytoplasmic viral nucleic acid sensors can recognize bacterial infection (8). It is notable that PRRs can recognize damage-associated molecular patterns (DAMPs), which are released from host cells via necrosis caused by cell stress and damage (9).

There are several reports showing that bacterial infection promotes the reprogramming of human somatic cells. Ohta and colleagues reported that lactic acid bacteria (LAB) could induce the expression of a subset of pluripotent stem cell marker genes, such as NANOG, OCT3/4, and SOX2 in human somatic cells (10). Moreover, *Mycobacterium leprae* infection also induces the expression of stem cell markers, CD73, CD44, Sca-1, and CD29, in Schwann cells (10). Similar to a bacterial infection, cell damage or stress also induces the expression of stem cell-specific genes. For instance, pluripotent multilineage-differentiating stress-enduring (Muse) cells are stem cells that could be isolated by treating cells with various types of stresses, such as long-term collagenase treatment, serum deprivation, low temperatures, and hypoxia (11). Severe cell stress leads to necrosis or necroptosis, resulting in the release of DAMPs, which can be recognized by PRRs.

The relation of the activation of PRRs and efficient reprogramming of cells has been previously implied. Lee J et al. reported that poly I:C promotes the expression of Oct4, Sox2, and NANOG, and that is required for efficient nuclear reprogramming in the induction of pluripotency (12). The role of RLRs on the expression of Oct3/4 was also reported (13). However, their underlying mechanisms have not yet been fully elucidated. In this study, we investigated the molecular mechanism of poly I:C-induced expression of the stem cell-specific genes. Our data indicate that cytoplasmic poly I:C as well as dsRNA activate the MAVS adaptor of RLRs and induces the expression of stem cell-specific genes via the transcription factor IRF1.

**Results**

**Cytoplasmic poly I:C induces Oct3/4 expression via MAVS**

To investigate the effect of poly I:C on the expression of stem cell-specific genes, human fibroblast BJ cells, which are frequently used to generate induced pluripotent stem cells (iPS cells) (14), were stimulated with poly I:C by several methods as follows. Addition of poly I:C to the cell culture medium is known to induce type I IFN expression via the TLR3-mediated signaling pathway (15). When poly I:C was added to the cell culture medium, IFN-β mRNA expression was increased upon stimulation (Fig. 1A); however, the Oct3/4 mRNA levels were not increased (Fig. 1B). DOTAP is a transfection reagent and is known to enforce endosomal translocation of nucleic acids (16-18). Poly I:C transfected using DOTAP are delivered to the endosomes, and thus stimulating TLR3, and leading to type I IFN expression via the TLR3-mediated signaling pathway (15). When poly I:C was added to the cell culture medium, IFN-β mRNA expression was increased upon stimulation (Fig. 1A); however, the Oct3/4 mRNA levels were not increased (Fig. 1B). DOTAP is a transfection reagent and is known to enforce endosomal translocation of nucleic acids (16-18). Poly I:C transfected using DOTAP are delivered to the endosomes, and thus stimulating TLR3, and leading to type I IFN expression (3,18). Similar to the addition of poly I:C to the cell culture medium, poly I:C transfection using DOTAP induced IFN-β mRNA expression (Fig. 1A) but did not increase the Oct3/4 mRNA levels (Fig. 1B).

Next, we tested the stimulation of BJ cells by transfecting with poly I:C using Lipofectamine 2000, which results in the activation of cytoplasmic viral RNA sensors, RIG-I and MDA5 (19). Oct3/4 mRNA levels were markedly increased by transfection with poly I:C using the Lipofectamine 2000 reagent (Fig. 1B). TBK1 and IRF-3 phosphorylation are required for type I IFN expression after poly I:C stimulation, and phosphorylation of the proteins was detected in BJ cells upon transfection with poly I:C using Lipofectamine 2000 reagent, and knockdown of MAVS suppressed phosphorylation (Fig 1C). To confirm the protein expression of the Oct3/4 upon stimulation, we performed confocal microscopy.
Although the Oct3/4 protein was not detected in unstimulated BJ cells, nuclear localization of the protein was detected 24 hr after poly I:C transfection using Lipofectamine 2000 as observed in cells infected with Sendai virus vector carrying Oct3/4 (SeV with Oct3/4) (Fig. 1D). LX-2 is a human hepatic stellate cell line, and transfection with poly I:C using Lipofectamine 2000 also increased Oct3/4 mRNA expression; moreover, the nuclear localization of Oct3/4 was detected in stimulated LX-2 cells (Fig. 1, E and F), suggesting that poly I:C-mediated Oct3/4 expression is not specific to BJ cells.

We next investigated the effect of other PAMPs on Oct3/4 expression. Salmon sperm DNA and synthesized oligo poly dA:dT were transfected into BJ cells, and the expression levels of type I IFN and Oct3/4 were determined. Unlike poly I:C, transfection with salmon sperm DNA and oligo dA:dT using Lipofectamine 2000 failed to increase Oct3/4 mRNA levels; however, it successfully induced IFN-β mRNA expression (Fig. 1, G and H). These data suggest that cGAS and/or TLR9 are not required for the Oct3/4 expression.

Cytoplasmic poly I:C is recognized by cytoplasmic viral RNA sensors, RIG-I and MDA5. Both RIG-I and MDA5 require the MAVS adaptor molecule to induce downstream signaling. Therefore, we next investigated the effect of MAVS knockdown on Oct3/4 expression upon stimulation. siRNA for MAVS reduced MAVS mRNA levels in BJ cells (Fig. 2A). We confirmed that siRNA for MAVS significantly reduced IFN-β mRNA levels in cells transfected with poly I:C using Lipofectamine 2000 (Fig. 2B). siRNA for MAVS significantly reduced Oct3/4 mRNA levels (Fig. 2C). NANOG is a stem cell-specific gene, and its expression was also increased by transfection with poly I:C using Lipofectamine 2000 (Fig. 2D). Similar to Oct3/4 expression, NANOG expression was reduced by siRNA for MAVS (Fig. 2D). siRNA for MAVS hardly reduced IFN-β mRNA expression upon poly I:C stimulation using DOTAP (Fig. 2E). These data indicate that cytoplasmic poly I:C increases Oct3/4 and NANOG expression in a MAVS-dependent manner.

The expression of stem cell-specific genes

induced by cytoplasmic dsRNA

Takahashi K and Yamanaka S selected 24 genes as candidates for factors that induce pluripotency in somatic cells, and Oct3/4, Sox2, c-Myc, and Klf4 were revealed to be crucial for inducing pluripotent stem cells (20). Later studies showed that the other candidate genes also contribute to the efficient generation of pluripotent stem cells (21). Because poly I:C transfection using Lipofectamine 2000 induced the expression of Oct3/4 and NANOGL as described above, we next measured the expression levels of the 24 genes upon stimulation.

In addition to Oct3/4 and NANOGL, the expression levels of SOX2, KLF4, c-Myc, REX1, SALL, DPPA2, DPPA3, ECAT1, DPPA4, and SOX15 were markedly increased by poly I:C transfection using Lipofectamine 2000 (Fig. 3). We could not detect the expression of DNMT3L, DPPA5, ERAS, FTHL17, GDF3, TCL1A, and UTF1 in BJ cells even in the presence or absence of poly I:C transfection (Fig. 3). Stimulation with poly I:C exhibited a marginal effect on the expression of β-catenine, ECAT8, FBOX15, GRB2, and STAT3 (Fig. 3). These data suggest that cytoplasmic poly I:C enhanced the expression of genes that contribute to the efficient generation of pluripotent stem cells.

Poly I:C is a synthetic analog of viral dsRNA, and the 3' UTR of HCV RNA is well-known to be recognized by RIG-I (22). Therefore, we prepared two types of HCV RNAs. First, 3' UTR dsRNA was synthesized in vitro by T7 RNA polymerase and used for stimulation. Second, we prepared total RNA samples of O cells that contained HCV replicons, which are HCV genomic RNA replicating in host cells (23). Total RNA of O cells, in which HCV replicons were removed by type I IFN treatment, was used for a negative control (24). We confirmed that in vitro synthesized 3' UTR of HCV RNA increased IFN-β mRNA levels (Fig. 4A). Interestingly, the expression levels of Oct3/4 as well as SOX2, KLF4, and c-Myc were increased by transfection with 3' UTR HCV RNA using Lipofectamine 2000, as cytoplasmic poly I:C did (Fig. 4, B–E). In contrast, transfection with 3' UTR HCV RNA using DOTAP failed to increase Oct3/4, SOX2, KLF4, and c-Myc, but successfully increased IFN-β mRNA expression levels (Fig. 4, F–J).
Nuclear localization of the Oct3/4 protein was detected by transfection with 3' UTR HCV RNA using Lipofectamine 2000 (Fig. 4K). These data indicate that not only poly I:C, but also in vitro synthesized HCV RNA can induce Oct3/4 expression in human BJ cells.

In contrast to in vitro synthesized HCV RNA, transfection with total RNA extracted from O cells using Lipofectamine 2000 did not increase the expression of Oct3/4, although O cell total RNA increased the expression of IFN-β mRNA (Fig. 4A). Since O cells contain HCV replicons, these data imply that the amount of HCV RNA in O cells is not sufficient to induce the Oct3/4 expression. When we compared the expression of Oct3/4 mRNA levels in O cells with those of OC cells, we could not detect any significant difference (Fig. 4L). These data suggest that some specific conditions, such as large amount of cytoplasmic dsRNA, are required for RIG-I and MDA5 to induce Oct3/4 mRNA expression (see Discussion).

**IRF1 is required for Oct3/4 expression in BJ cells**

To reveal the underlying mechanism, we investigated the role of the factors of the innate immunity in cytoplasmic dsRNA-mediated Oct3/4 expression. Since cytoplasmic poly I:C leads to the production of type I IFN, it is possible that type I IFN induces Oct3/4 expression after poly I:C stimulation. To test this hypothesis, siRNA for STAT1 was used to inhibit type I IFN receptor signaling. siRNA for STAT1 substantially reduced STAT1 mRNA expression (Fig. 5A). Contrary to what we expected, siRNA for STAT1 hardly reduced poly I:C-mediated Oct3/4 mRNA expression (Fig. 5A), suggesting that type I IFN signaling does not play a major role in the Oct3/4 expression. siRNA for STAT1 moderately reduced IFN-β mRNA expression upon poly I:C stimulation (Fig. 5A). Considering that RIG-I is an interferon inducible gene, it is possible that basal expression of type I IFN affected RIG-I expression, thereby STAT1 knockdown reduced RIG-I-mediated type I IFN expression.

To further test whether type I IFN signaling is responsible for Oct3/4 mRNA expression, we next used siRNA for STAT2, anti-IFNAR2 neutralization antibodies, and a JAK inhibitor. siRNA for STAT2 exhibited only marginal effect on the Oct3/4 expression (Fig 5B). Anti-IFNAR antibodies reduced the expression of an IFN-inducible gene IFIT-1; however, it failed to reduce Oct3/4 mRNA expression (Fig. 5C). In addition, stimulation with IFN-α itself could not increase Oct3/4 mRNA expression (Fig. 5C). Moreover, a JAK inhibitor failed to reduce the expression of Oct3/4 and NANOG mRNAs (Fig. 5, D and E). These data also suggest that type I IFN does not plays a major role in poly I:C-mediated Oct3/4 mRNA expression.

Considering that Oct3/4 expression in BJ cells requires MAVS, we reasoned that transcription factors that are downstream of MAVS would be responsible for Oct3/4 expression. The transcription factors IRF1, IRF3, AP-1, and NF-κB transcription factors are reported to be activated by MAVS-dependent signaling. We identified the binding motifs of IRF1, AP-1, and NF-κB on the promoter region of Oct3/4, SOX2, KLF4, c-Myc, and NANOG (Fig. 6A). To test the role of NF-κB in Oct3/4 expression, we used BAY11-7082, an inhibitor for NF-κB. Although the inhibitor markedly reduced IFN-β and TNF-α expression upon stimulation with the 3' UTR of HCV RNA and poly I:C, it exhibited a marginal effect on Oct3/4 expression (Fig. 6B).

Next, we tested the roles of IRF1 and c-Jun by using siRNAs, which substantially reduced their mRNA levels (Fig. 6C). Knockdown of c-Jun hardly reduced the expression of IFN-β, Oct3/4, and NANOG upon poly I:C stimulation (Fig. 6D). In contrast, knockdown of IRF1 reduced the mRNA levels of Oct3/4 and NANOG after poly I:C stimulation (Fig. 6D), suggesting that IRF1 is involved in the Oct3/4 expression upon RLR stimulation. In contrast to Oct3/4 and NANOG, siRNA for IRF1 reduced KLF4 mRNA expression at only later time point (24 hr post stimulation) and failed to reduce the mRNA expression of SOX2 and c-Myc (Fig. 7A). These data imply that not only IRF1 but also other transcription factors might be required for the expression.

To further investigate the role of IRF1, subcellular localization of IRF1 was observed before and after stimulation, because IRF1 is known to translocate to the nuclei after its activation. IRF1 nuclear localization was observed...
after stimulation with poly I:C using lipofectamine 2000 (Fig. 7B). This data suggests that IRF1 was upregulated and translocated into the nuclei after RLR stimulation. TLR3 activation also induced the IRF1 nuclear localization (Fig S1), implying that other transcription factors as well as IRF1 are involved in the Oct3/4 expression. To further investigate the involvement of IRF1 in Oct3/4 expression, we performed chromatin immunoprecipitation (ChIP) assay with anti-IRF1 antibody. Poly I:C stimulation using lipofectamine 2000 increased the amount of precipitated Oct3/4 promoter region with anti-IRF1 antibody (Fig. 7C). Taken together, our data indicate that RIG-I and MDA5-induced IRF1 activation is involved in the expression of Oct3/4 mRNA.

Discussion

The role of PRRs in the reprogramming of somatic cells has been reported; however, the underlying mechanism has not yet been fully elucidated. In this study, we investigated the effect of extracellular and cytoplasmic poly I:C and dsDNA, and found that cytoplasmic poly I:C increased Oct3/4 expression and induced its nuclear localization in human somatic cells more efficiently than extracellular/cytoplasmic dsDNA or extracellular poly I:C did. Interestingly, cytoplasmic poly I:C-induced Oct3/4 expression requires MAVS and IRF1 transcription factors. These observations indicate that the cytoplasmic poly I:C, which is recognized by RIG-I and MDA5, activate the MAVS protein, leading to Oct3/4 expression via the activation of IRF-1 transcription factor. IRF1 was critical for the Oct3/4 expression. However, since IRF1 activation was also detected after TLR3 expression, we do not exclude the possibility that not only IRF1 but also other transcription factors are involved in Oct3/4 expression.

MAVS is a solo adaptor of RIG-I and MDA, and it localizes on the mitochondria and peroxisome (25,26). In the innate immune response, mitochondrial MAVS activates IRF3 and NF-κB, which results in the expression of type I IFNs and other pro-inflammatory cytokines. In contrast, peroxisomal MAVS activates IRF1 and induces the interferon-stimulated genes (26). Considering that IRF1 is required for poly I:C-mediated Oct3/4 expression, we hypothesize that the activation of peroxisomal MAVS is required for the Oct3/4 expression.

Previous studies reported that poly I:C-mediated expression of Oct3/4 is required for TLR3 and its adaptor TICAM-1 (12). Based from our results, poly I:C-mediated Oct3/4 expression was largely dependent on the MAVS adaptor but not TICAM-1. However, these observations do not exclude the possibility that the TLR3 and TICAM-1 pathways induce the expression of the stem cell-specific genes in other types of somatic cells or in other experimental conditions. Several innate immune responses might be involved in the efficient reprogramming in the induction of pluripotency.

There are several reports on how severe cell stress triggers the expression of stem cell-specific genes. Isolation of Muse cells requires several severe cell stresses, and cells referred to as stimulus-triggered acquisition of pluripotency (STAP) cells require acidic conditions (11,27). Severe cell stress would induce necrosis and necroptosis, leading to the release of DAMPs, such as RNA and DNA. Recent studies reported that host RNA functions as a ligand for RIG-I and MDA5 (28,29), and myeloid cells have the ability to incorporate extracellular RNA into their cytoplasm, thereby activating the innate immune responses via RIG-I and MDA5 (30,31). Therefore, it is possible that severe cell stresses lead to the release of host RNA, which results in its internalization into the cytoplasm, thereby activating the MAVS-IRF1 signaling pathway and leading to Oct3/4 mRNA expression. However, further studies are still required to reveal the underlying mechanism.

In our experimental conditions, cytoplasmic poly I:C and in vitro-synthesized viral RNA induced Oct3/4 mRNA expression, but Oct3/4 mRNA did not increase by stimulation with a physiological amount of viral RNA. These observations imply that mere viral infection hardly increases Oct3/4 expression. Considering that extracellular RNAs are easily internalized into the cytoplasm of myeloid cells, leading to activation of RIG-I and MDA5 (31), it is expected that RIG-I and MDA5 require some specific conditions, such as release of large amount of dsRNA from viral infected dead cells, to increase...
Oct3/4 mRNA expression. Niwa H showed that the acidic conditions markedly increased Oct3/4 expression in a small population of cells; however, he could not reproduce the STAP phenomenon (27). We also could not detect any STAP phenomenon by using poly I:C, but we detected a substantial increase in the expression of stem cell-specific genes. Thus, unlike the induction of four Yamanaka factors, the activation of the innate immune system would be insufficient for inducing pluripotency. Although the physiological significance of cytoplasmic dsRNA-induced expression of stem cell-specific genes is still unclear, we expect that chemicals targeting of the molecules involved in the MAVS-IRF1 pathway, such as RIG-I, MDA5, MAVS, IRF1, Riplet, and ZNF598 (32,33), may be useful in increasing the efficiency of the production of iPS cells.

**Experimental Procedures**

**Cells and reagents**

Human foreskin fibroblast BJ cells (early passage, p6) were purchased from Stemgent. Human hepatic stellate cell lines LX2 cells were provided by T. Shimotohno (NCGM) (34). Human hepatocyte cell lines Oe cells and Oc cells that contained HCV 1b replicons were provided by N. Kato (Okayama University) (35). All cells were grown in D-MEM (Gibco) supplemented with 10% FCS and penicillin-streptomycin (Gibco). Additionally, L-Glutamine (Gibco) and NEAA (Gibco) were supplemented for both O cells and Oc cells, and G418 (Roche) was added for O cells. NEAA and pyruvate sodium (Gibco) were supplemented for LX2 cells. Poly I:C was purchased from GE Healthcare company, and dissolved in saline. Human IFN-α and TGF-β were purchased from Miltenyi Biotec and R&D systems, respectively. An anti-OCT3/4 antibody was purchased from Cell Signaling Technology, Inc. An anti-IFNAR2 antibody was purchased from PBL. Anti-MAVS and anti-IRF1 antibodies were purchased from CST. MAVS, AP1, IRF1, STAT1, and STAT2 siRNAs were purchased from Thermo Fisher Scientific. Ruxolitinib was purchased from Chemscene LLC (Funakoshi). Detection of phosphorylation of TBK1 and IRF were performed as described previously (32).

**RNA preparation**

Total RNA from the human hepatocyte cell lines Oe cells and Oc cells were extracted using TRIzol reagent (Thermo Fisher Scientific). HCV genotype 1b 3’ UTR RNA including the poly U/UC region was synthesized using T7 and SP6 RNA polymerase and purified with TRIzol, as described previously. These RNAs were transfected into cells using either Lipofectamine 2000 or DOTAP (Roche).

**Quantitative PCR**

For quantitative PCR (qPCR), total RNA was extracted using TRIzol reagent (Invitrogen), after which 0.5 μg of RNA was reverse transcribed using a high capacity cDNA transcription kit with an RNase inhibitor (Applied Biosystems) according to the manufacturer’s instructions. qPCR was performed using a Step One Real-Time PCR system (Applied Biosystems). The expression of mRNA was normalized to that of GAPDH mRNA, and the fold change was determined by dividing the expression levels in each sample by that in the control samples in each experiment. The PCR primers sequences are listed in table 1.

**Confocal microscopy**

Anti-OCT4 rabbit mAb was purchased from Cell Signaling Technology, Inc. Cells were fixed with 3% formaldehyde in 1x PBS for 30 min, and permeabilized with 0.2% Triton X-100 in 1x PBS for 15 min. For blocking, 1% BSA in PBS was used for 30 min. The cells were labeled with the anti OCT4 antibody over night at 4 ºC. After washing four times with 1% BSA in PBS, cells were incubated with an Alexa 488-conjugated secondary antibody and 1% BSA in PBS for 60 min at room temperature, and then were washed four times with 1% BSA in PBS. Samples were mounted on glass slides using Prolong Gold (Invitrogen). Cells were visualized at a magnification of ×63 using an LSM510 META microscope (Zeiss).

**ChIP assay**

4 x 10⁶ of BJ cells were transfected with short poly I:C. O and 6 hrs after transfection cells were subjected to ChIP assay, according to the manufactures instructions (CST #9002). Briefly,
cells were fixed with formaldehyde and lysed, and genomic DNA was partially digested with Micrococcal Nuclease treatment. Immunoprecipitation was performed with anti-IRF1 antibody and control IgG. To elute genomic DNA from protein-DNA complex, immunoprecipitates were treated with 1 x ChIP Elution Buffer at 65 °C over 2 hrs. Eluted DNA was purified with spin columns. PCR was performed with primers, Oct3/4 promoter F and R.

Statistical Analysis

$t$-test were performed using MS-Excel software. Error bars represent standard deviation (n > 3, *p < 0.05). All experiments were repeated at least two times. ND represents "not detected", and NS represents "not significant".
Acknowledgements: We would like to thank all our laboratory members for helpful discussion.

Conflict of Interest: The authors declare that they have no conflict of interest with the contents of this article.

Author contributions: KM, GW, MO, TK, HT, KF, and TS designed the experiments and analyzed the data. KM and MO performed quantitative PCR analyses and confocal microscopy. HO and TS wrote the paper. KM performed knockdown study. TS supervised this study.

References
1. Kawai, T., and Akira, S. (2011) Toll-like receptors and their crosstalk with other innate receptors in infection and immunity. *Immunity* 34, 637-650
2. Takaoka, A., and Yamada, T. (2019) Regulation of signaling mediated by nucleic acid sensors for innate interferon-mediated responses during viral infection. *Int Immunol*
3. Matsumoto, M., and Seya, T. (2008) TLR3: interferon induction by double-stranded RNA including poly(I:C). *Adv Drug Deliv Rev* 60, 805-812
4. Yoneyama, M., Kikuchi, M., Natsukawa, T., Shinobu, N., Imaizumi, T., Miyagishi, M., Taira, K., Akira, S., and Fujita, T. (2004) The RNA helicase RIG-I has an essential function in double-stranded RNA-induced innate antiviral responses. *Nat Immunol* 5, 730-737
5. Hemmi, H., Takeuchi, O., Kawai, T., Kaisho, T., Sato, S., Sanjo, H., Matsumoto, M., Hoshino, K., Wagner, H., Takeda, K., and Akira, S. (2000) A Toll-like receptor recognizes bacterial DNA. *Nature* 408, 740-745
6. Li, X. D., Wu, J., Gao, D., Wang, H., Sun, L., and Chen, Z. J. (2013) Pivotal roles of cGAS-cGAMP signaling in antiviral defense and immune adjuvant effects. *Science* 341, 1390-1394
7. Sun, L., Wu, J., Du, F., Chen, X., and Chen, Z. J. (2013) Cyclic GMP-AMP synthase is a cytosolic DNA sensor that activates the type I interferon pathway. *Science* 339, 786-791
8. Zevini, A., Olagnier, D., and Hiscott, J. (2017) Crosstalk between Cytoplasmic RIG-I and STING Sensing Pathways. *Trends Immunol* 38, 194-205
9. Newton, K., and Dixit, V. M. (2012) Signaling in innate immunity and inflammation. *Cold Spring Harb Perspect Biol* 4
10. Ito, N., and Ohta, K. (2015) Reprogramming of human somatic cells by bacteria. *Dev Growth Differ* 57, 305-312
11. Bhartiya, D. (2017) Pluripotent Stem Cells in Adult Tissues: Struggling To Be Acknowledged
Over Two Decades. Stem Cell Rev 13, 713-724

12. Lee, J., Sayed, N., Hunter, A., Au, K. F., Wong, W. H., Mocarski, E. S., Pera, R. R., Yakubov, E., and Cooke, J. P. (2012) Activation of innate immunity is required for efficient nuclear reprogramming. Cell 151, 547-558

13. Sayed, N., Ospino, F., Himmati, F., Lee, J., Chanda, P., Mocarski, E. S., and Cooke, J. P. (2017) Retinoic Acid Inducible Gene 1 Protein (RIG1)-Like Receptor Pathway Is Required for Efficient Nuclear Reprogramming. Stem Cells 35, 1197-1207

14. Takahashi, K., Tanabe, K., Ohnuki, M., Narita, M., Ichisaka, T., Tomoda, K., and Yamanaka, S. (2007) Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 131, 861-872

15. Alexopoulou, L., Holt, A. C., Medzhitov, R., and Flavell, R. A. (2001) Recognition of double-stranded RNA and activation of NF-kappaB by Toll-like receptor 3. Nature 413, 732-738

16. Almofti, M. R., Harashima, H., Shinohara, Y., Almofti, A., Baba, Y., and Kiwada, H. (2003) Cationic liposome-mediated gene delivery: biophysical study and mechanism of internalization. Arch Biochem Biophys 410, 246-253

17. Yasuda, K., Yu, P., Kirchning, C. J., Schlatter, B., Schmitz, F., Heit, A., Bauer, S., Hochrein, H., and Wagner, H. (2005) Endosomal translocation of vertebrate DNA activates dendritic cells via TLR9-dependent and -independent pathways. J Immunol 174, 6129-6136

18. Itoh, K., Watanabe, A., Funami, K., Seya, T., and Matsumoto, M. (2008) The clathrin-mediated endocytic pathway participates in dsRNA-induced IFN-beta production. J Immunol 181, 5522-5529

19. Loo, Y. M., and Gale, M., Jr. (2011) Immune signaling by RIG-I-like receptors. Immunity 34, 680-692

20. Takahashi, K., and Yamanaka, S. (2006) Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 126, 663-676

21. Takahashi, K., and Yamanaka, S. (2016) A decade of transcription factor-mediated reprogramming to pluripotency. Nat Rev Mol Cell Biol 17, 183-193

22. Saito, T., Owen, D. M., Jiang, F., Marcotrigiano, J., and Gale, M., Jr. (2008) Innate immunity induced by composition-dependent RIG-I recognition of hepatitis C virus RNA. Nature 454, 523-527
23. Oshiumi, H., Ikeda, M., Matsumoto, M., Watanabe, A., Takeuchi, O., Akira, S., Kato, N., Shimotohno, K., and Seya, T. (2010) Hepatitis C virus core protein abrogates the DDX3 function that enhances IPS-1-mediated IFN-beta induction. *PLoS One* **5**, e14258

24. Ikeda, M., Abe, K., Dansako, H., Nakamura, T., Naka, K., and Kato, N. (2005) Efficient replication of a full-length hepatitis C virus genome, strain O, in cell culture, and development of a luciferase reporter system. *Biochem Biophys Res Commun* **329**, 1350-1359

25. Seth, R. B., Sun, L., Ea, C. K., and Chen, Z. J. (2005) Identification and characterization of MAVS, a mitochondrial antiviral signaling protein that activates NF-kappaB and IRF 3. *Cell* **122**, 669-682

26. Dixit, E., Boulant, S., Zhang, Y., Lee, A. S., Odendall, C., Shum, B., Hacohen, N., Chen, Z. J., Whelan, S. P., Fransen, M., Nibert, M. L., Superti-Furga, G., and Kagan, J. C. (2010) Peroxisomes are signaling platforms for antiviral innate immunity. *Cell* **141**, 668-681

27. Niwa, H. (2016) Investigation of the cellular reprogramming phenomenon referred to as stimulus-triggered acquisition of pluripotency (STAP). *Sci Rep* **6**, 28003

28. Zhao, Y., Ye, X., Dunker, W., Song, Y., and Karijolich, J. (2018) RIG-I like receptor sensing of host RNAs facilitates the cell-intrinsic immune response to KSHV infection. *Nat Commun* **9**, 4841

29. Malathi, K., Dong, B., Gale, M., Jr., and Silverman, R. H. (2007) Small self-RNA generated by RNase L amplifies antiviral innate immunity. *Nature* **448**, 816-819

30. Nguyen, T. A., Smith, B. R. C., Tate, M. D., Belz, G. T., Barrios, M. H., Elgass, K. D., Weisman, A. S., Baker, P. J., Preston, S. P., Whitehead, L., Garnham, A., Lundie, R. J., Smyth, G. K., Pellegrini, M., O’Keeffe, M., Wicks, I. P., Masters, S. L., Hunter, C. P., and Pang, K. C. (2017) SIDT2 Transports Extracellular dsRNA into the Cytoplasm for Innate Immune Recognition. *Immunity* **47**, 498-509 e496

31. Kato, H., Takeuchi, O., Sato, S., Yoneyama, M., Yamamoto, M., Matsui, K., Uematsu, S., Jung, A., Kawai, T., Ishii, K. J., Yamaguchi, O., Otsu, K., Tsujimura, T., Koh, C. S., Reis e Sousa, C., Matsuura, Y., Fujita, T., and Akira, S. (2006) Differential roles of MDA5 and RIG-I helicases in the recognition of RNA viruses. *Nature* **441**, 101-105

32. Wang, G., Kouwaki, T., Okamoto, M., and Oshiumi, H. (2019) Attenuation of the Innate Immune Response against Viral Infection Due to ZNF598-Promoted Binding of FAT10 to RIG-I. *Cell Rep*
Cadena, C., Ahmad, S., Xavier, A., Willemsen, J., Park, S., Park, J. W., Oh, S. W., Fujita, T., Hou, F., Binder, M., and Hur, S. (2019) Ubiquitin-Dependent and -Independent Roles of E3 Ligase RIPLET in Innate Immunity. *Cell* **177**, 1187-1200

Hendrickson, H., Chatterjee, S., Cao, S., Morales Ruiz, M., Sessa, W. C., and Shah, V. (2003) Influence of caveolin on constitutively activated recombinant eNOS: insights into eNOS dysfunction in BDL rat liver. *Am J Physiol Gastrointest Liver Physiol* **285**, G652-660

Ariumi, Y., Kuroki, M., Abe, K., Dansako, H., Ikeda, M., Wakita, T., and Kato, N. (2007) DDX3 DEAD-box RNA helicase is required for hepatitis C virus RNA replication. *J Virol* **81**, 13922-13926
FOOTNOTES
Funding was supported by Grants-in-Aid from the Ministry of Education, Science, and Technology (MEXT).

Table 1. Primer sequences for PCR

| Gene    | F               | R               |
|---------|-----------------|-----------------|
| GAPDH   | 5'-GAGTCAACGGATTTGGCTCGT-3' | 5'-TTGATTTTGCAAGGATCTCG-3' |
| IFN-β   | 5'-CAACTTGCTTGAGTTCTTCTACAAAG-3' | 5'-TATTCAAGCCTCCATTCAATTG-3' |
| OCT3/4  | 5'-CCGGAAGCCTGAGAAGAGAG-3' | 5'-GCAGATGTCGTTGGCTGA-3' |
| SOX2    | 5'-CCCCTTTATTTCCGTAGTTGATTTTT-3' | 5'-TGGATTTCTCGGCAGACTGATT-3' |
| KLF4    | 5'-TACCAAGAGCTCATGCCACC-3' | 5'-GCAGATTTCATCCACAGCC-3' |
| c-MYC   | 5'-GCCACGTCTCCACACATCACG-3' | 5'-TCTTTGGCAGCAGGATAGCCTT-3' |
| NANOG   | 5'-AGAACTCTCCACACATCCTGAACCT-3' | 5'-TGCCACCTCTTATGATTTTCTTCT-3' |
| β-CATEIN| 5'-TGCAGTTCCCTTCTATGAT-3' | 5'-GATGTGCACGAACAAGCAAC-3' |
| REX1    | 5'-ACAGAAGACAAGAGGCTGTCTAC-3' | 5'-GTCTTTGGCTTTTCTTTCAG-3' |
| ECAT1   | 5'-TGACATGACAGCTGGTGAC-3' | 5'-GCCTCCCGGACTTCTTATG-3' |
| DPPA2   | 5'-GCAAGAATTGTGGCTGAAGAGC-3' | 5'-TTGTGGTGCTGCCAGAGAAGTC-3' |
| DPPA3   | 5'-GTTACTGGCGGAGTTCTGTA-3' | 5'-TGAAGTGGCTTGTTGCTTCTG-3' |
| DPPA4   | 5'-GCCAGGAAACATCAGCAAAAGAG-3' | 5'-CAGAATGTCCTCGGTGAATCAG-3' |
| Gene   | Forward Primer (5' to 3') | Reverse Primer (5' to 3') |
|--------|--------------------------|--------------------------|
| DPPA5  | 5'-TCACCGAGGTCTGTTTAC-3' | 5'-TTGGGTGGAAACTTTCAC-3' |
| ECAT8  | 5'-CCTGGCAAGAATTCTTGCA-3' | 5'-CCTGGCAAGAATTCTTGCA-3' |
| GDF3   | 5'-CGGGAATGTACTCGCTTTC-3' | 5'-TGGGCCAACATGCAACTGTT-3' |
| FTHL17 | 5'-TCACCGGCAATTCTTCAC-3' | 5'-TCGAGTTGCTGTGCACTT-3' |
| SOX15  | 5'-AGCAGAGGCTTTGGGTAC-3' | 5'-TTAGGTGGCAAGCTTCCAG-3' |
| STAT3  | 5'-CCTGGCAAGAATTCTTGCA-3' | 5'-TCGTCTCACTGGTCAGCTTC-3' |
| UTF1   | 5'-ACCCGCTTGACTTGACCTTGA-3' | 5'-TTGAACATACCCAAGAGGG-3' |
| ERAS   | 5'-TCATGGAGGTCTGCAACAC-3' | 5'-TTGGTCAGCTTGGAATTGTCAG-3' |
| DNMT3L | 5'-ATGCTACTGCTGGAGTTGGTG-3' | 5'-CTGTTTCAAGATCTCAAGG-3' |
| GRB2   | 5'-ACGAGCTGGACTTAAAAGG-3' | 5'-TTTCTTCTGCCCTGCTGCT-3' |
| FBXO15 | 5'-CCATGCTAGCATATTGTC-3' | 5'-TAGGCGCTAGATCGAGTGAG-3' |
| TCL1A  | 5'-GGCTCTGGCTTTGGTTTAC-3' | 5'-GCAACCGTAACTGTAACCTATCC-3' |
| SALL4  | 5'-CCAATAGTCAAGGCGAAAGC-3' | 5'-ATGTTGCGAGGAACTCTTCAACC-3' |
| STAT1  | 5'-TTCAGGAAGACCCAAATCCAG-3' | 5'-TGAATTCTGCTGAACTCG-3' |
| JUN    | 5'-ACCTTGAAGCTCAGAACTCG-3' | 5'-GTTTGCAACTGCTGTTAG-3' |
IRF1

F  5'-ACATCCAGTGGAAGTTGTG-3'
R  5'-TTCCCTTCCTCATCCTCATC-3'

Oct3/4 promoter

F  5'-CACTCCAGTCTGGCAACAAAG-3'
R  5'-AAACGGGAGACAACTGG-3'
Figure 1. Cytoplasmic poly I:C induces the expression of Oct3/4 mRNA

(A, B) BJ cells were stimulated by adding 50 µg/ml poly I:C to the cell culture medium (polyI:C), transfecting 1µg/mL poly I:C using DOTAP (Dotap), and transfecting 1µg/mL poly I:C using Lipofectamine 2000 reagent (Lipofectamine 2000). Total RNA was extracted at the indicated time points, and the expression levels of IFN-β (A) and Oct3/4 (B) mRNA were determined by RT-qPCR and normalized to those of GAPDH.

(C) siRNAs for control and MAVS were transfected into BJ cells. 2 days later, 1µg/mL poly I:C was transfected into BJ cells with Lipofectamine 2000, and whole cell extracts were prepared at indicated time points. Proteins were detected with indicated antibodies.

(D) 1µg/mL poly I:C was transfected into BJ cells with (-) or without Lipofectamine 2000 (poly I:C). For control, SeV vector expressing Oct3/4 was transfected into BJ cells. 0, 8, and 24 hrs after transfection, cells were fixed and stained with anti-Oct3/4 antibody. The protein was detected by an Alexa Fluor 488-conjugated secondary antibody (green). Nuclei were stained with DAPI (blue) to compare the localization of Oct3/4 and nuclei. The white bar represents 10 µm.

(E, F) LX-2 cells were transfected with 1 µg/mL poly I:C using Lipofectamine2000. Total RNA was extracted at indicated time points, and mRNA levels were determined by RT-qPCR and normalized to those of GAPDH (E). Twenty-four hours after stimulation, cells were fixed and labelled with anti-Oct3/4 antibody. The proteins were detected with secondary antibody conjugated to Alexa Fluor 488 (green), and nuclei were stained with DAPI (blue) (F). The white bar represents 10 µm.

(G, H) 1 µg/mL salmon sperm DNA and poly dA:dT were transfected into BJ cells using Lipofectamine 2000, and total RNA was extracted at indicated time points. IFN-β (G) and Oct3/4 (H) mRNA levels were determined by RT-qPCR and normalized to those of GAPDH.
Figure 2. MAVS is required for poly I:C-mediated Oct3/4 mRNA expression

(A–E) siRNAs for MAVS (siMAVS) and negative control (siControl) were transfected into BJ cells; 2 days after transfection, BJ cells were stimulated by 1 µg/mL poly I:C transfection using Lipofectamine 2000 (A–D) or using DOTAP (E), and total RNA was extracted at indicated time points. The expression levels of MAVS (A), IFN-β (B, E), Oct3/4 (C), and NANOG (D) mRNA were determined by RT-qPCR and normalized to those of GAPDH.
Figure 3. Cytoplasmic poly I:C increases the expression levels of stem cell-specific genes

1 µg/mL poly I:C was transfected into BJ cells using Lipofectamine 2000, and total RNA was extracted at indicated time points. The expression levels of indicated genes were determined by RT-qPCR and normalized to those of GAPDH. ND represents not detected.
Figure 4. In vitro synthesized 3’ UTR of HCV RNA induces Oct3/4 mRNA expression

(A–J) 3’ UTR of HCV RNA (HCV RNA) was in vitro synthesized by T7 RNA polymerase. Total RNA samples were extracted from O cell and Oc cells; 1 µg/mL each RNA sample was transfected into BJ cells using Lipofectamine 2000 (A–E) and Dotap (F–J), and then total RNA was extracted at indicated time points. The expression levels of IFN-β, Oct3/4, Sox2, KLF4, and c-Myc were determined by RT-qPCR and normalized to those of GAPDH.

(K) 1 µg/mL 3’ UTR of HCV RNA and poly I:C was transfected into BJ cells using Lipofectamine 2000; 24 hours after transfection, cells were fixed and labelled with anti-Oct3/4 antibody. The protein was stained with a secondary antibody conjugated to Alexa Fluor 488 (green). Nuclei were stained with DAPI (blue). The white bar represents 10 µm.

(L) HCV RNA and Oct3/4 mRNA levels in O and Oc cells were determined by RT-qPCR.
Figure 5. Type I IFN was dispensable for poly I:C-mediated Oct3/4 expression

(A, B) siRNAs for STAT1 (siSTAT1) (A), STAT2 (siSTAT2) (B), and negative control (siControl) (A, B) were transfected into BJ cells; 2 days after transfection, transfected cells were stimulated by transfection with 1 µg/mL poly I:C using Lipofectamine 2000 for 12 hr, and then total RNA was extracted. The expression levels of STAT1, IFN-β, and Oct3/4 were determined by RT-qPCR and normalized to those of GAPDH.

(C) BJ cells were treated with mock, isotype control IgG, and anti-IFNAR2 antibodies, and then transfected with HCV RNA and poly I:C using Lipofectamine 2000 or treated with type I IFN for 12 h. The expression levels of IFIT-1 and Oct3/4 mRNA were determined by RT-qPCR and normalized to those of GPDH.

(D, E) BJ cells were treated with 3 nM of JAK inhibitor, Ruxolitinib for 12 hr, and then cells were stimulated with poly I:C using Lipofectamine 2000 in the presence of the inhibitor, and the mRNA expression of Oct3/4 (D) and NANOG (E) was determined by RT-qPCR.
Figure 6. IRF1 is involved in poly I:C-mediated Oct3/4 expression

(A) Schematic representation of the binding sites of transcription factors on the promoter regions of Oct3/4, SOX2, KLF4, c-Myc, and NANOG.

(B) BJ cells treated with BAY11-7082, an inhibitor for NF-κB, were stimulated by transfecting with 1 µg/mL poly I:C and 3’ UTR of HCV RNA using Lipofectamine2000 for 6 hours. Total RNA was extracted, and the expression levels of IFN-β, TNF-α, and Oct3/4 mRNA were determined by RT-qPCR and normalized to those of GAPDH.

(C and D) siRNAs for negative control, IRF-1, and Jun were transfected into BJ cells. 48 hours after transfection, cells were stimulated by transfecting with 1 µg/mL poly I:C by using Lipofectamine2000. Total RNA was extracted at indicated time points. The expression levels of IRF1, JUN, IFN-β, Oct3/4, and Nanog mRNA were determined by RT-qPCR, and normalized to those of GAPDH.
Figure 7. IRF1 activation after poly I:C stimulation
(A) siRNAs for IRF1 and negative control were transfected into BJ cells. 48 hours after transfection, cells were stimulated by transfection of 1 µg/mL poly I:C using Lipofectamine 2000. RT-qPCR was performed to determine the expression levels of SOX2, KLF4, and c-Myc mRNAs.
(B) BJ cells were stimulated with 1 µg/mL poly I:C using Lipofectamine 2000. Cells were fixed and stained with DAPI and anti-IRF1 antibody at 0 and 5 hr after stimulation. IRF1 (red) and nuclei (blue) were observed by fluorescence confocal microscopy (left panel). % of the cells with IRF1 nuclear localization was measured (right panel). The with bar represents 10 µm.
(C) BJ cells were stimulated with 1 µg/mL poly I:C using Lipofectamine 2000. Cells were then fixed, and ChIP assay was performed with control IgG and anti-IRF1 antibody. Oct3/4 promoter DNA fragments were detected by PCR, and their amounts were normalized to those of mock samples.
Cytoplasmic dsRNA induces the expression of \textit{OCT3/4} and \textit{NANOG} mRNAs in differentiated human cells

Guanming Wang, Takahisa Kouwaki, Kazuki Mugikura, Masaaki Okamoto, Hiromi Takaki, Kenji Funami, Tsukasa Seya and Hiroyuki Oshiumi

\textit{J. Biol. Chem.} \textit{published online October 15, 2019}

Access the most updated version of this article at doi: 10.1074/jbc.RA119.009783

Alerts:
- When this article is cited
- When a correction for this article is posted

Click here to choose from all of JBC's e-mail alerts